AIM ImmunoTech CEO and President Thomas K Equels Acquires $6,550 in Common Shares

PUBT · 1d ago
AIM ImmunoTech CEO and President Thomas K Equels Acquires $6,550 in Common Shares
  • AIM ImmunoTech CEO, President and director Thomas K. Equels purchased 50,000 shares of common stock at $0.131 each.
  • The purchase increased his direct beneficial ownership to 436,095 shares.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. AIM ImmunoTech Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001493152-26-053379), on November 20, 2026, and is solely responsible for the information contained therein.